Literature DB >> 12797959

Unique role of dystroglycan in peripheral nerve myelination, nodal structure, and sodium channel stabilization.

Fumiaki Saito1, Steven A Moore, Rita Barresi, Michael D Henry, Albee Messing, Susan E Ross-Barta, Ronald D Cohn, Roger A Williamson, Kathleen A Sluka, Diane L Sherman, Peter J Brophy, James D Schmelzer, Phillip A Low, Lawrence Wrabetz, M Laura Feltri, Kevin P Campbell.   

Abstract

Dystroglycan is a central component of the dystrophin-glycoprotein complex implicated in the pathogenesis of several neuromuscular diseases. Although dystroglycan is expressed by Schwann cells, its normal peripheral nerve functions are unknown. Here we show that selective deletion of Schwann cell dystroglycan results in slowed nerve conduction and nodal changes including reduced sodium channel density and disorganized microvilli. Additional features of mutant mice include deficits in rotorod performance, aberrant pain responses, and abnormal myelin sheath folding. These data indicate that dystroglycan is crucial for both myelination and nodal architecture. Dystroglycan may be required for the normal maintenance of voltage-gated sodium channels at nodes of Ranvier, possibly by mediating trans interactions between Schwann cell microvilli and the nodal axolemma.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2003        PMID: 12797959     DOI: 10.1016/s0896-6273(03)00301-5

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  101 in total

Review 1.  Extracellular matrix: functions in the nervous system.

Authors:  Claudia S Barros; Santos J Franco; Ulrich Müller
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-01-01       Impact factor: 10.005

Review 2.  The Nodes of Ranvier: Molecular Assembly and Maintenance.

Authors:  Matthew N Rasband; Elior Peles
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-09-09       Impact factor: 10.005

3.  GMPPB-Associated Dystroglycanopathy: Emerging Common Variants with Phenotype Correlation.

Authors:  Braden S Jensen; Tobias Willer; Dimah N Saade; Mary O Cox; Tahseen Mozaffar; Mena Scavina; Vikki A Stefans; Thomas L Winder; Kevin P Campbell; Steven A Moore; Katherine D Mathews
Journal:  Hum Mutat       Date:  2015-09-23       Impact factor: 4.878

4.  C. elegans dystroglycan coordinates responsiveness of follower axons to dorsal/ventral and anterior/posterior guidance cues.

Authors:  Robert P Johnson; James M Kramer
Journal:  Dev Neurobiol       Date:  2012-07-27       Impact factor: 3.964

5.  A dual role for Integrin α6β4 in modulating hereditary neuropathy with liability to pressure palsies.

Authors:  Yannick Poitelon; Vittoria Matafora; Nicholas Silvestri; Desirée Zambroni; Claire McGarry; Nora Serghany; Thomas Rush; Domenica Vizzuso; Felipe A Court; Angela Bachi; Lawrence Wrabetz; Maria Laura Feltri
Journal:  J Neurochem       Date:  2018-02-13       Impact factor: 5.372

Review 6.  Laminins in peripheral nerve development and muscular dystrophy.

Authors:  Wei-Ming Yu; Huaxu Yu; Zu-Lin Chen
Journal:  Mol Neurobiol       Date:  2007-06       Impact factor: 5.590

Review 7.  The dystroglycanopathies: the new disorders of O-linked glycosylation.

Authors:  Paul T Martin
Journal:  Semin Pediatr Neurol       Date:  2005-09       Impact factor: 1.636

8.  Muscle-specific expression of LARGE restores neuromuscular transmission deficits in dystrophic LARGE(myd) mice.

Authors:  Jessica D Gumerson; Carol S Davis; Zhyldyz T Kabaeva; John M Hayes; Susan V Brooks; Daniel E Michele
Journal:  Hum Mol Genet       Date:  2012-12-06       Impact factor: 6.150

Review 9.  The scales and tales of myelination: using zebrafish and mouse to study myelinating glia.

Authors:  Sarah D Ackerman; Kelly R Monk
Journal:  Brain Res       Date:  2015-10-20       Impact factor: 3.252

10.  Targeting Schwann cells by nonlytic arenaviral infection selectively inhibits myelination.

Authors:  Anura Rambukkana; Stefan Kunz; Jenny Min; Kevin P Campbell; Michael B A Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.